In light of this finding, we investigated the possibility that by blocking CtBP1/BARS functions with Comp.11, we could prevent melanoma progression by increasing the BRCA1/BRIP1-controlled DNA-Damage Response Pathway [95]. Here, BRCA1 is linked to melanoma.